HALOZYME THERAPEUTICS, INC. — Balance Sheet Charts
8 snapshots of history · ending 2025-12-31 · SEC EDGAR
Source:10-K · 10-Q
Assets vs Liabilities
Cash Position Breakdown
Debt Structure
Working Capital Components
Total Assets↑+22.4% +$462M
$2.53B
Current Assets↓-24.0% -$260M
$825M
Cash & Equivalents↑+15.5% +$18M
$134M
ST Investments
—
Receivables↑+47.9% +$138M
$426M
Inventory↑+24.4% +$35M
$176M
Net PPE↑+8.8% +$4M
$44M
Goodwill↑+39.2% +$164M
$580M
Intangibles↑+144.2% +$580M
$981M
Total Liabilities↑+45.7% +$777M
$2.48B
Current Liabilities↑+27.3% +$38M
$177M
Account Payables↑+103.9% +$11M
$21M
Long-Term Debt↑+42.3% +$637M
$2.14B
Stockholders Equity↓-86.6% -$315M
$49M
Retained Earnings↓-84.8% -$305M
$55M
Operating Lease ROU Asset↑+10.3% +$4M
$38M
Operating Lease Liability↑+12.6% +$4M
$35M
Gross PP&E↑+17.1% +$11M
$78M
Accumulated Depreciation↑+30.4% +$8M
$33M
Inventory Raw Materials↓-8.9% -$2M
$22M
Inventory WIP↑+2.5% +$751K
$31M
Inventory Finished Goods↑+1.1% +$2M
$144M
Debt Due Y1↑+28.5% +$3M
$12M
Debt Due Y2↑+2299.9% +$212M
$221M
Debt Due Y3↓-40.8% -$331M
$481M
Debt Due Y4↓-99.1% -$718M
$7M
Debt Due Y5
$7M
Debt Due >Y5
$1.51B
Total Debt Carrying Amount↑+44.7% +$674M
$2.18B
Contract Asset
$20M
Contract Liability↑+243.1% +$25M
$35M
Contract Liability (Current)
—
Contract Liability (Noncurrent)
—
Remaining Performance Obligation
—